Paradigm Biopharmaceuticals Ltd. (PBIGF)

OTHER OTC:PBIGF

PBIGF

Paradigm Biopharmaceuticals

RESEARCH TOOLSreports

Paradigm Biopharmaceuticals (PBIGF) Price & Analysis

Compare

17 Followers

PBIGF Stock Chart & Stats

$0.24

-$0.01(-3.72%)

At close: Jan 06 4:00 PM EST

$0.24

-$0.01(-3.72%)

Day’s Range― - ―

52-Week Range$0.13 - $0.35

Previous CloseN/A

Volume2.27K

Average Volume (3M)1.65K

Market Cap

$78.77M

Enterprise Value$99.80M

Total Cash (Recent Filing)$14.66M

Total Debt (Recent Filing)$1.01M

Price to Earnings (P/E)―

Beta-0.22

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding444,908,140

10 Day Avg. Volume200

30 Day Avg. Volume1,650

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.53

Price to Sales (P/S)1840.42

P/FCF Ratio-6.00

Enterprise Value/Market Cap1.27

Enterprise Value/Revenue1.65K

Enterprise Value/Gross Profit-1.02K

Enterprise Value/Ebitda-2.45

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.07

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetExtremely low debt relative to equity materially reduces refinancing and interest-rate risk for a development-stage biotech. This conservative leverage provides durable financial flexibility to fund clinical programs, pursue partnerships or time capital raises more strategically over the next 2–6 months.

Narrowing FY2025 Net LossA materially narrower net loss in FY2025 signals operating progress and cost control steps that can persist beyond quarter-to-quarter noise. Sustained improvement in net losses improves financing prospects, reduces immediate funding pressure, and strengthens the company's ability to execute its midterm development plan.

Reduced Cash Burn Versus Prior YearA sharp reduction in cash outflow versus FY2024 extends the company's operational runway and lessens near-term financing needs. Even if still negative, a durable downtrend in burn improves strategic optionality, enabling staged development or partnership timing over the coming months.

Bears Say

Minimal, Volatile RevenueVery small and inconsistent revenue undermines sustainable growth and limits ability to achieve operating scale. Persistent top-line volatility hampers margin expansion, weakens commercial leverage, and makes forecasting and multi-period resource allocation difficult for long-term product development.

Deeply Negative ProfitabilityConsistent, deep losses erode equity and indicate the business has not achieved break-even economics. Over time, persistent negative profitability pressures returns on capital, increases reliance on external funding, and raises dilution risk for shareholders if trends do not reverse.

Ongoing Negative Cash FlowChronic negative operating and free cash flow means the company cannot self-fund development and must access capital markets or partners. This structural dependence on external financing increases execution risk, potential dilution and constrains long-term strategic choices absent sustained cash-flow improvement.

Paradigm Biopharmaceuticals News

Paradigm Expands Global Phase 3 Osteoarthritis Trial to Hong Kong and Moldova

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has activated a new clinical trial site...

7d ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for 5.65 Million New Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an announcement. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

11d ago

Paradigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals reported a net loss before tax of...

28d ago

Paradigm Biopharmaceuticals Updates Market on Director Paul Rennie’s Equity Holdings

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an update. Paradigm Biopharmaceuticals has disclosed changes in director Paul Rennie’s...

1M ago

Paradigm Biopharmaceuticals Updates Market on Director Option Lapse

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has disclosed a change in...

1M ago

Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals announced that a Paradigm-supported study of pentosan...

1M ago

Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an update. Paradigm Biopharmaceuticals has signed a binding term sheet with...

2M ago

Paradigm Biopharmaceuticals Director Converts Options Into Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has disclosed a change in the interests...

2M ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied to the ASX for quotation...

2M ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

2M ago

PBIGF FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?

Paradigm Biopharmaceuticals Ltd. lowest stock price was $0.13 and its highest was $0.35 in the past 12 months.

What is Paradigm Biopharmaceuticals Ltd.’s market cap?

Paradigm Biopharmaceuticals Ltd.’s market cap is $78.77M.

When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?

Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 155 days.

How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?

Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -$0.039 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.039.

Is Paradigm Biopharmaceuticals Ltd. overvalued?

According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Paradigm Biopharmaceuticals Ltd. pay dividends?

Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.

What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?

Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?

Paradigm Biopharmaceuticals Ltd. has 444,908,140 shares outstanding.

What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?

Paradigm Biopharmaceuticals Ltd. reported an EPS of -$0.039 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in PBIGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Paradigm Biopharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-265.55%

Trailing 12-Months

Asset Growth

-29.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.